The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in immunologically cold pancreatic, gallbladder, and biliary cancers.
 
Brian Hemendra Ramnaraign
No Relationships to Disclose
 
Ji-Hyun Lee
No Relationships to Disclose
 
azka ali
No Relationships to Disclose
 
Sherise C. Rogers
No Relationships to Disclose
 
Jesus C. Fabregas
No Relationships to Disclose
 
Ryan M. Thomas
No Relationships to Disclose
 
Carmen Joseph Allegra
No Relationships to Disclose
 
Ilyas Sahin
No Relationships to Disclose
 
David L. DeRemer
Leadership - Hematology/Oncology Pharmacy Association
Honoraria - Bristol-Myers Squibb (I); Pfizer (I); Pharmacy Times; Pharmacy Times
 
Thomas J. George
Consulting or Advisory Role - Pfizer; Tempus
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Seagen (Inst)
 
Jonathan Alexander Chatzkel
Travel, Accommodations, Expenses - Lilly; Merck